- Home
- DBD vs RARE Comparison
DBD vs RARE Comparison
Compare DBD & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | RARE |
|---|---|---|
| Founded | 1859 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DBD | RARE |
|---|---|---|
| Price | $81.24 | $22.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $90.00 | $66.32 |
| AVG Volume (30 Days) | 295.3K | ★ 2.3M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | 7.31 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $3,805,700,000.00 | $673,000,000.00 |
| Revenue This Year | $3.56 | $17.23 |
| Revenue Next Year | $3.25 | $36.13 |
| P/E Ratio | $31.89 | ★ N/A |
| Revenue Growth | 1.46 | ★ 20.13 |
| 52 Week Low | $34.88 | $18.41 |
| 52 Week High | $84.42 | $43.51 |
Technical Indicators
Market Signals| Indicator | DBD | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 71.97 | 39.51 |
| Support Level | $79.48 | $19.63 |
| Resistance Level | $84.42 | $22.16 |
| Average True Range (ATR) | 3.03 | 1.35 |
| MACD | 1.04 | -0.10 |
| Stochastic Oscillator | 79.84 | 34.27 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.